Mirzaten Q-Tab (Mirtazapine)

• Mirtazapine is used in the treatment of depressive disorders, acting on noradrenergic and serotonergic pathways.
• Major depressive disorder: improves mood, sleep and appetite in adult patients.
• Treatment‑resistant depression: may be added as adjunct therapy when first‑line agents are insufficient.
• Depression with anxiety: helps reduce both depressive and anxiety symptoms.

• Mirtazapine antagonizes central presynaptic α2‑adrenergic receptors, increasing norepinephrine release, and blocks postsynaptic 5‑HT2 and 5‑HT3 receptors, enhancing serotonergic transmission. Potent H1‑receptor antagonism contributes to its sedative and appetite‑stimulating effects, collectively producing antidepressant activity.

Mirtazapine may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects

• Sedation or drowsiness: especially at treatment initiation.
• Increased appetite and weight gain: often observed with continued use.
• Dry mouth: may lead to mild discomfort.
• Constipation: can be managed with dietary measures.

Serious or Rare Side Effects

• Agranulocytosis or neutropenia: requires regular blood monitoring.
• Seizures: reported rarely, particularly in predisposed individuals.
• Severe allergic reactions: including rash, angioedema or anaphylaxis.

Before prescribing Mirzaten Q-Tab, clinicians should consider several safety aspects.

• Weight monitoring: due to potential weight gain.
• Sedation assessment: advise patients about operating machinery.
• Hepatic impairment: dose adjustment may be needed.
• Discontinuation: avoid abrupt cessation to reduce withdrawal symptoms.
• Elderly patients: start at lower doses and monitor for confusion.

Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Mirtazapine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis.
• CNS depressants (e.g., benzodiazepines, alcohol): additive sedation.
• Other serotonergic agents: potential serotonin syndrome.

Moderate Interactions (Monitor Closely)

• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine levels.
• Antihypertensive drugs: possible additive blood pressure lowering.
• Anticholinergic medications: may exacerbate dry mouth and constipation.
• Oral contraceptives: may alter hormonal efficacy.